SEARCH

SEARCH BY CITATION

References

  • Alawneh J. A., Moustafa R. R. and Baron J. C. (2009) Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke 40, e443e450.
  • Arenillas J. F., Rovira A., Molina C. A., Grivé E., Montaner J. and Alvarez-Sabín J. (2002) Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke 33, 21972203.
  • Barker P. E., Wagner P. D., Stein S. E., Bunk D. M., Srivastava S. and Omenn G. S. (2006) Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the National Institute of Standards and Technology-National Cancer Institute Standards, methods, assays, reagents and technologies workshop, August 18-19, 2005. Clin. Chem. 52, 16691674.
  • Bath P. M. W., Blann A., Smith N. and Butterworth R. J. (1998) Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 9, 155159.
  • Brott T. and Bogousslavsky J. (2000) Treatment of acute ischemic stroke. N. Engl. J. Med. 343, 710722.
  • Brott T. G., Haley E. C., Jr, Levy D. E. et al. (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23, 632640.
  • De Marchis G. M., Katan M., Weck A. et al. (2013) Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 80, 12781286.
  • DeLong E. R., DeLong D. M. and Clarke-Pearson D. L. (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837845.
  • Desilles J. P., Meseguer E., Labreuche J. et al. (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: A registry and systematic review. Stroke 44, 19151923.
  • Efstathiou S. P., Tsiakou A. G., Tsioulos D. I., Panagiotou T. N., Pefanis A. V., Achimastos A. D. and Mountokalakis T. D. (2007) Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin. Chim. Acta 378, 7885.
  • Ernoult E., Bourreau A., Gamelin E. and Guette C. (2010) A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J. Biomed. Biotechnol. 2010, 927917.
  • Fragnoud R., Yugueros-Marcos J., Pachot A. and Bedin F. (2012) Isotope coded protein labeling analysis of plasma specimens from acute severe dengue fever patients. Proteome Sci. 10, 60.
  • Grube M. M., Koennecke H.-C., Walter G., Meisel A., Sobesky J., Nolte C. H., Wellwood I. and Heuschmann P. U. (2013) Influence of acute complications on outcome 3 months after ischemic stroke. PLoS ONE 8, e75719.
  • Jickling G. C. and Sharp F. R. (2011) Blood biomarkers of ischemic stroke. Neurotherapeutics 8, 349360.
  • Jung T., Schrader N., Hellwig M., Enssle K. H. and Neumann C. (1999a) Soluble human interleukin-4 receptor is produced by activated T cells under the control of metalloproteinases. Int. Arch. Allergy Immunol. 119, 2330.
  • Jung T., Wagner K., Neumann C. and Heusser C. H. (1999b) Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur. J. Immunol. 29, 864871.
  • Karp N. A. and Lilley K. S. (2009) Investigating sample pooling strategies for DIGE experiments to address biological variability. Proteomics 9, 388397.
  • Kendziorski C., Irizarry R. A., Chen K. S., Haaq J. D. and Gould M. N. (2005) On the utility of pooling biological samples in microarray experiments. Proc. Natl Acad. Sci. USA 102, 42524257.
  • Lin L. C., Lee T. H., Chang C. H. et al. (2012) Predictors of clinical deterioration during hospitalization following acute ischemic stroke. Eur. Neurol. 67, 186192.
  • Liu K. X., Chen S. Q., Zhang H., Guo J. Y., Li Y. S. and Huang W. Q. (2009) Intestinal ischaemia/reperfusion upregulates β-defensin-2 expression and causes acute lung injury in the rat. Injury 40, 950955.
  • Mehta S. L., Manhas N. and Raghubir R. (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 54, 3466.
  • Mendioroz M., Fernández-Cadenas I., Alvarez-Sabín J. et al. (2009) Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients. Cerebrovasc. Dis. 28, 143150.
  • Mendioroz M., Fernández-Cadenas I., Rosell A., Delgado P., Domingues-Montanari S., Ribó M., Penalba A., Quintana M., Alvarez-Sabín J. and Montaner J. (2011) Osteopontin predicts long-term functional outcome among ischemic stroke patients. J. Neurol. 258, 486493.
  • Montaner J., Alvarez-Sabín J., Molina C., Anglés A., Abilleira S., Arenillas J., González M. A. and Monasterio J. (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32, 17591766.
  • Montaner J., Fernandez-Cadenas I., Molina C. A., Ribó M., Huertas R., Rosell A., Penalba A., Ortega L., Chacón P. and Alvarez-Sabín J. (2006) Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37, 12051210.
  • Montaner J., García-Berrocoso T., Mendioroz M. et al. (2012) Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovasc. Dis. 34, 240245.
  • Nickel D., Busch M., Mayer D., Hagemann B., Knoll V. and Stenger S. (2012) Hypoxia triggers the expression of human β defensin 2 and antimicrobial activity against Mycobacterium tuberculosis in human macrophages. J. Immunol. 188, 40014007.
  • O'Neill P. A., Davies I., Fullerton K. J. and Bennett D. (1991) Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22, 842847.
  • Pencina M. J., D'Agostino R. B., D'Agostino R. B. and Vasan R. S. (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157172.
  • Pepe M. S., Janes H., Longton G., Leisenring W. and Newcomb P. (2004) Limitations of the Odds Ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159, 882890.
  • Pickering J. W. and Endre Z. H. (2012) New metrics for assessing diagnostic potential of candidate biomarkers. Clin. J. Am. Soc. Nephrol. 7, 13551364.
  • Roger V. L., Go A. S., Lloyd-Jones D. M. et al. (2012) Heart disease and stroke statistics–2012 update: A report from the american heart association. Circulation 125, e2e220.
  • Roquer J., Rodríguez-Campello A., Gomis M. et al. (2008) Acute stroke unit care and early neurological deterioration in ischemic stroke. J. Neurol. 255, 10121017.
  • Schröder J. M. and Harder J. (1999) Human beta-defensin-2. Int. J. Biochem. Cell Biol. 31, 645651.
  • Sham P., Bader J. S., Craig I., O'Donovan M. and Owen M. (2002) DNA pooling: a tool for large-scale association studies. Nat. Rev. Genet. 3, 862871.
  • Smith C. J., Emsley H. C. A., Gavin C. M. et al. (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 4, 2.
  • Tiszlavicz Z., Somogyvári F., Szolnoki Z., Sztriha L. K., Németh B., Vécsei L. and Mándi Y. (2012) Genetic polymorphisms of human β-defensins in patients with ischemic stroke. Acta Neurol. Scand. 126, 109115.
  • Vila N., Castillo J., Dávalos A. and Chamorro A. (2000) Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31, 23252329.
  • Walker L. C., Thompson B. A., Waddell N. and kConFab Investigators, Grimmond S.M. and Spurdle A.B. (2010) Use of DNA-Damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. PLoS Genet. 6, e1000850.
  • Welsh P., Barber M., Langhorne P., Rumley A., Lowe G. D. and Stott D. J. (2009) Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 27, 247253.
  • Whiteley W., Chong W. L., Sengupta A. and Sandercock P. (2009) Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40, e380e389.
  • Whiteley W., Wardlaw J., Dennis M., Lowe G., Rumley A., Sattar N., Welsh P., Green A., Andrews M. and Sandercock P. (2012) The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 43, 8691.
  • Worthmann H., Tryc A. B., Goldbecker A., Ma Y. T., Tountopoulou A., Hahn A., Dengler R., Lichtinghagen R. and Weissenborn K. (2010) The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis. 30, 8592.
  • Zaremba J., Ilkowski J. and Losy J. (2006) Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischemic stroke. Folia Neuropathol. 44, 282289.
  • Zeng L., Liu J., Wang Y., Wang L., Weng S., Chen S. and Yang G. Y. (2013) Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur. Neurol. 69, 6875.
  • Zhang W., Carriquiry A., Nettleton D. and Dekkers J. C. M. (2007) Pooling mRNA in microarray experiments and its effect on power. Bioinformatics 23, 12171224.
  • del Zoppo G. J., Levy D. E., Wasiewski W. W., Pancioli A. M., Demchuk A. M., Trammel J., Demaerschalk B. M., Kaste M., Albers G. W. and Ringelstein E. B. (2009) Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40, 16871691.